Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
13.50 +0.35    +2.66%
01/03 - Closed. Currency in USD ( Disclaimer )
After Hours
13.40
-0.10
-0.74%
23:30:00 - Real-time Data
  • Volume: 9,042,748
  • Bid/Ask: 13.32 / 13.50
  • Day's Range: 13.12 - 13.56
Type:  Equity
Market:  United States
Teva ADR 13.50 +0.35 +2.66%

NYSE:TEVA Financials

 
See below for an overview of the Teva financial reports. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track the NYSE:TEVA financials over time.

Teva Pharmaceutical Industries Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 15,846 million compared to USD 14,925 million a year ago. Net loss was USD 559 million compared to USD 2,446 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 2.2 a year ago. Diluted loss per share from continuing operations was USD 0.5 compared to USD 2.2 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

TEVA Income Statement

Gross margin TTM 48.25%
Operating margin TTM 20.07%
Net Profit margin TTM -3.53%
Return on Investment TTM 9.11%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 4457 3850 3878 3661
Gross Profit 2669 1851 1796 1582
Operating Income 988 761 670 498
Net Income 80 -863 -205

TEVA Balance Sheet

Quick Ratio MRQ 0.54
Current Ratio MRQ 1.02
LT Debt to Equity MRQ 241.95%
Total Debt to Equity MRQ 270.09%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 43479 42088 43095 43456
Total Liabilities 35353 34577 35387 34845
Total Equity 8126 7511 7708 8611

TEVA Cash Flow Statement

Cash Flow/Share TTM 1.22
Revenue/Share TTM 14.14
Operating Cash Flow  9.67%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1184 5 324 -145
Cash From Investing Activities 184 302 181
Cash From Financing Activities -576 -55 -706
Net Change in Cash -420 494 -658
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rafi Shoev
Rafi Shoev Jan 22, 2024 23:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva 125years of developing new drugs bigest jeneic company andto be leader in biosimilar drugs.
Rafi Shoev
Rafi Shoev Jan 17, 2024 14:23
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva free cash flew aoutsyrnding
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
24.02.24 Alboteck and teva .Humira biosimilar on the top of the day.from FDA.finally.
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Freecash is very intresting???
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very atractiv ???
Rafi Shoev
Rafi Shoev Jan 15, 2024 10:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva revenew my hope will be more than 17.5bilions.
Rafi Shoev
Rafi Shoev Jan 12, 2024 19:41
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If your stock is dawn its probably a time to by more.
Rafi Shoev
Rafi Shoev Jan 12, 2024 16:26
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Concidering to sturting by back .
Rafi Shoev
Rafi Shoev Jan 12, 2024 15:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The humira biosomilar wil be agaim changer
Rafi Shoev
Rafi Shoev Jan 12, 2024 14:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jaint phrma is nomber one in tell aviv stock.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email